The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population

Liver International

Volumn 31, Issue 9, 2011, Pages 1326-1331

  Wang, Chih Wen ^a,b,c   Lin, Hsing Yi ^a,b   Shin, Shyi Jang ^b   Yu, Ming Lung ^b   Lin, Zu Yau ^b   Dai, Chia Yen ^b   Huang, Jee Fu ^b   Chen, Shinn Cherng ^b   Li, Steven Shoei Lung ^a   Chuang, Wan Long ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Chi Shan Hospital   (Taiwan)

Author keywords

Insulin resistance; Nonalcoholic fatty liver disease; PNPLA3 I148M polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; INSULIN; PATATIN LIKE PHOSPHOLIPASE 3; PHOSPHOLIPASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ECHOGRAPHY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; WAIST CIRCUMFERENCE;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INSULIN RESISTANCE; LIPASE; LIVER; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TAIWAN;

EID: 80052552852     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02526.x     Document Type: Article

References (36)

1. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
2. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
3. McCullough J. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40: S17-29.
4. Sookoian S, Castaño GO, Burgueño AL, et al. A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-6.
5. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
6. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52: 1056-60.
7. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903.
8. Foster KJ, Griffith AH, Dewbury K, Price CP, Wright R. Liver disease in patients with diabetes mellitus. Postgrad Med J 1980; 56: 767-72.
9. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological, and biochemical considerations. Pathol Annu 1989; 24: 275-302.
10. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352-6.
11. Yalow R, Berson S. Introduction and General Considerations. In Odell W and Daugheday W, eds. Principles of Competitive Protein Binding Assays., Philadelphia: J.B. Lippincott Co., 1971, 1-19.
12. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetología 1985; 28: 412-19.
13. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13-5.
14. Osawa H, Mori Y. Sonographic diagnosis of fatty liver using a histogram technique that compares liver and renal cortical amplitudes. J Clin Ultrasound 1996; 24: 25-9.
15. Zardi EM, De Sio I, Ghittoni G, et al. Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis?J Clin Gastroenterol 2011; 45: 59-63.
16. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
17. Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, et al. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J Gastroenterol 2007; 13: 3614-18.
18. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-82.
19. Lee JH, Rhee PL, Lee JK, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Kor J Intern Med 1998; 13: 12-4.
20. Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver in non-obese Asian men. J Gastroenterol Hepatol 2004; 19: 694-8.
21. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
22. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
23. Johansson LE, Lindblad U, Larsson CA, Råstam L, Ridderstråle MPolymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur J Endocrinol 2008; 159: 577-83.
24. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-15.
25. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-7.
26. Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 1995; 19: 841-45.
27. Strang BD, Bertics SJ, Grummer RR, Armentano LE. Relationship of triglyceride accumulation to insulin clearance and hormonal responsiveness in bovine hepatocytes. J Dairy Sci 1998; 81: 740-7.
28. Polonsky KS, Rubenstein AH.C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984; 33: 486-94.
29. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E829-35.
30. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000; 355: 2181-82.
31. Machado M, Cortez-Pinto HNASH, insulin resistance and iron. Liver Int 2006; 26: 1159-62.
32. Tuomainen TP, Diczfalusy U, Kaikkonen J, Nyyssönen K, Salonen JT. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med 2003; 35: 922-8.
33. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-52.
34. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-87.
35. Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53: 335-8.
36. Ma RC, Liu KH, Lam PM, et al. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96: 799-807.